Research Reports for Zynga, Pfizer, Lowe's, Fifth Third Bancorp, Staples, and Peabody Energy
VANCOUVER, British Columbia, May 30, 2012 /PRNewswire-Asia/ -- Insiderslab.com has issued insider trading reports and Equity Research for the following companies: Zynga (NASDAQ: ZNGA), Pfizer (NYSE: PFE), Lowe's (NYSE: LOW), Fifth Third Bancorp (NASDAQ: FITB), Staples (NASDAQ: SPLS), and Peabody Energy (NYSE: BTU).
(Read full report by clicking the link below, you may need to copy and paste the full link to your browser.)
Zynga, Inc. (NASDAQ: ZNGA): Zynga continued to tumble and slump 7.87% to US$6.09 after hitting a new low of US$5.98 earlier in the session. More than 48.20 million shares exchanged hands, more than double its average volume of 22.63 million shares. Shares of the company have been showing heavy selling pressure ever since Facebook, Inc. (NASDAQ: FB) made debut on the stock market on May 18, 2012. Zynga generated majority of its revenue from the world's largest social networking platform. Shares of Zynga have tumbled about 27% over the past one week, while shares of Facebook have fallen 25%. The company made debut in mid-December, 2011 at an IPO price of US$10. The stock quickly moved up to US$15.91, its new high, by early March, 2012. However, the rally was short lived and the stock started to see selling pressure. Late April, the company posted third quarter loss due to stock-compensation expenses. The company reported loss of US$85.4 million, or 12 cents a share, reversing a year ago profit of US$16.8 million. On an adjusted basis, the company would have earned 6 cents a share. Revenue during the quarter jumped 32% to US$321 million, from US$243 million a year ago. Insiderslab.com found Ko David Y, Chief Mobile Officer, sold about 18,523 shares on May 22 at price US$7.12. To increase investment return, Insiderslab.com refers insider trading data to professional investors as it believes that company insiders like Executive Officers and Directors have a better understanding about the company's prospects. Do you want to know when company insiders will buy their shares?
Read Full Report: http://www.insiderslab.com/PR3/053012B/ZNGA/Zynga.pdf
Pfizer Inc. (NYSE: PFE): Pfizer climbed US$0.05 or 0.23% to US$22.18 with over 30.75 million shares exchanged hands, compared to its average volume of 41.82 million shares. Last week, the company said that European Union regulators have given green signal to the company's kidney cancer drug known as Inlyta. The committee noted that the drug would be approved as a treatment for advanced renal cell carcinoma in adult patients. In another news, a U.S. health advisory panel did not vote in the company's favor to treat a rare neurodegenerative disease, stating that the data were not enough to justify the company's drug. Now, the U.S Food and Drug Administration will consider this decision while taking its final decision. Lately, the company announced to recall 650K units of Advil Liqui-Gels in March due to odor caused by over-processed gelatin. Shares of PFE have jumped 2.50% so far this year and have been moving within a range of US$30.75-US$41.82 over the past one week. Since insiders such as CEOs, CFOs and Directors have better access to company non-public information, Insiderslab.com thinks that investors would be wise to pay close attention to their stock trading behaviors. Check this insider trade report for PFE here.
Read Full Report: http://www.insiderslab.com/PR3/053012B/PFE/Pfizer.pdf
Lowe's Companies, Inc. (NYSE: LOW): Lowe's rose US$0.25 or 0.92% to US$27.49 with more than 18.14 million shares traded hands, compared to its average volume of 15.52 million shares. Last week, the stock was up over 8% after reporting solid first quarter earnings. The company said that profit during the latest quarter jumped to US$527 million, or 43 cents a share, from US$461 million, or 34 cents a share, whereas revenue surged 8% year over year to US$13.15 billion, from a year ago revenue of US$12.19 billion. Same-store sales grew 2.60% driven by 2.70% jump in U.S. However, the company trimmed its full year earnings target on lingering uncertainty in the global economy and underperformance of the housing market. The company now estimates to earn in the range of US$1.73 to US$1.83 a share, from its prior guidance of US$1.75 to US$1.85 a share. However, revenue is still expected to grow 1-2% during the year to 50.69 billion to US$51.2 billion. Analysts are targeting the company to report US$1.87 a share on revenue of US$50.94 billion. Shares of LOW have outperformed the broader market so far and jumped over 8%. Moreover, over the past one year, shares of the company have soared over 14%. The stock has been moving within a range of US$18.07 and US$32.29 over the past 52 weeks. Insiderslab.com believes that it is a clever way to check if insiders like CEOs, CFOs, and Directors in LOW are starting to buy more company shares. See insider trade report for LOW here.
Read Full Report: http://www.insiderslab.com/PR3/053012B/LOW/Lowes.pdf
Today Insiderslab.com also observed abnormal trade volume for the following companies; insiders may involve trading in these companies. It will take some time for insiders to report their trades. Read these reports and add these companies into your Insider Trade Radar.
Fifth Third Bancorp (NASDAQ: FITB)
Read Full Report: http://www.insiderslab.com/PR3/053012B/FITB/FifthThirdBancorp.pdf
Staples, Inc. (NASDAQ: SPLS)
Read Full Report: http://www.insiderslab.com/PR3/053012B/SPLS/Staples.pdf
Peabody Energy Corporation (NYSE: BTU)
Read Full Report: http://www.insiderslab.com/PR3/053012B/BTU/PeabodyEnergy.pdf
Insider Filing Source Reference: All observations, analysis and reports are based on public information released by the U.S. Securities and Exchange Commission.
Insiderslab.com covers insider trade data in major stock markets in the U.S., Hong Kong, Mainland China, and Singapore. Insiderslab.com features a team of experienced data analysts striving to provide the investment community with the tools, software, and data necessary to carry out more effective investment research.
Please visit insiderslab.com/disclaimers/disclaimers.php for details.
SOURCE Insiderslab.com; Insiders.hkBack to top